Barclays PLC Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Barclays PLC increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 410.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,045 shares of the company’s stock after acquiring an additional 197,033 shares during the quarter. Barclays PLC owned about 0.36% of EyePoint Pharmaceuticals worth $1,959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after buying an additional 4,172 shares during the last quarter. Greenwich Wealth Management LLC raised its position in shares of EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after purchasing an additional 900 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after purchasing an additional 7,953 shares in the last quarter. Cyndeo Wealth Partners LLC purchased a new stake in EyePoint Pharmaceuticals during the 3rd quarter valued at about $100,000. Finally, Arizona State Retirement System increased its stake in EyePoint Pharmaceuticals by 9.7% during the 2nd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after purchasing an additional 1,171 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Stock Performance

EYPT stock opened at $7.58 on Friday. The business’s 50-day moving average is $9.44 and its two-hundred day moving average is $9.04. The company has a market cap of $517.34 million, a price-to-earnings ratio of -3.79 and a beta of 1.45. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $6.90 and a fifty-two week high of $30.99.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Scotiabank began coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 target price on the stock. Chardan Capital upped their price objective on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Robert W. Baird reduced their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, November 11th. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.71.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.